Biomea Fusion is trading at $0.88, down 30.46%, following the company’s announcement of Phase 1 results for oral GLP-1 candidate BMF-650; available coverage does not establish what specifically prompted the decline. - The results showed weight reduction and generally mild-to-moderate adverse events. - Reporting noted a steep after-hours decline following the announcement. - XBI is down 2.01%; the sector move alone does not explain the much larger share decline.